Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
A new triple gene therapy called ProSavin might safely improve motor function in Parkinson's patients by reprogramming brain cells to produce dopamine - a chemical essential for the proper control of movement - according to a phase 1/2 trial published in The Lancet.
"Lack of dopamine results in the tremors, limb stiffness, and loss of balance that characterise Parkinson's", explains study leader Professor Stéphane Palfi from AP-HP, Groupe Henri-Mondor Albert-Chenevier in Créteil, France.
"ProSavin uses an inert virus to deliver three dopamine-making genes directly into the striatum region of the brain that controls movement, with the aim of converting non dopamine-producing striatal neurons [nerve cells] into dopamine-producing factories to replace the constant source of dopamine that is lost in Parkinson's disease."*
Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's, affecting around 5 million people worldwide. The symptoms of Parkinson's are due to loss of dopamine-producing nerve cells in the part of the brain responsible for controlling movement.
The most widely used treatment is the drug levodopa, a precursor of dopamine that can cross the blood-brain barrier. However, over time cell death is so great that effectiveness lessens and patients can develop involuntary muscle spasms (dyskinesias) and other side effects.
The current study tested the safety, tolerability, and efficacy of three different doses of ProSavin in 15 individuals aged 48 to 65 years with advanced Parkinson's disease who were no longer responding well to other treatments.
Patients were rated on a Parkinson's disease scale of motor functions that includes speech, tremors, rigidity, finger taps, posture, gait, and bradykinesia (slow movement). The lower the rating, the better the function.
All patients injected with ProSavin had only mild to moderate side-effects related to the treatment; the most common being on-medication dyskinesias (20 events, 11 patients) and on-off phenomena (12 events, nine patients).
Significant improvements in motor scores were seen in all patients in the off-medication state (when patients had been off their medications for 12 hours) at both 6 months (38 vs 26) and 12 months (38 vs 27) after surgery.
However, the authors warn, "Although the efficacy findings show promise, the magnitude of effects are within the placebo range reported in other clinical trials for Parkinson's disease using surgical techniques, and must be interpreted with caution."
They conclude, "[Our findings suggest that this] therapeutic approach that provides continuous and stable dopamine replacement, restricted to the dopamine-depleted striatum, might provide an effective long-term treatment without the onset of behavioural complications." Writing in a linked Comment, A Jon Stoessl from the University of British Columbia, Vancouver, Canada says, "The approach taken by Palfi and colleagues is novel in that it is the first time that lentiviral vectors have been successfully applied to the treatment of neurological disease in humans and does not depend on survival of dopaminergic neurons, but rather assumes that transfected striatal neurons preserved in Parkinson's disease will develop the capacity to synthesise dopamine."
However, he adds, "Despite numerous imperfections, we have reasonably good treatments for the motor manifestations of Parkinson's disease in the form of levodopa, infusion therapies, and deep brain stimulation. The challenge of Parkinson's disease is the management of nonmotor problems, many of which have a non-dopamine basis. The therapy described here will not address these issues, but the safety of the approach could be seen as a proof of principle for future studies focused on rigorous assessment of efficacy as well as targeting these devastating problems."
*Quote direct from author and cannot be found in text of Article.
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial, Prof Stéphane Palfi MD, Jean Marc Gurruchaga MD, G Scott Ralph PhD, Helene Lepetit PhD, Sonia Lavisse PhD, Philip C Buttery PhD, Colin Watts PhD, James Miskin PhD, Michelle Kelleher PhD, Sarah Deeley MSc, Hirokazu Iwamuro MD, Jean Pascal Lefaucheur MD, Claire Thiriez MD, Gilles Fenelon MD, Cherry Lucas BA, Pierre Brugières MD, Inanna Gabriel MD, Kou Abhay MD, Xavier Drouot MD, Naoki Tani MD, Aurelie Kas MD, Prof Bijan Ghaleh MD, Philippe Le Corvoisier MD, Patrice Dolphin MSc, David P Breen MRCP, Sarah Mason BS, Natalie Valle Guzman MSc, Prof Nicholas D Mazarakis PhD, Pippa A Radcliffe PhD, Richard Harrop PhD, Susan M Kingsman PhD, Prof Olivier Rascol MD, Stuart Naylor PhD, Prof Roger A Barker PhD, Philippe Hantraye PhD, Prof Philippe Remy MD, Prof Pierre Cesaro MD, Kyriacos A Mitrophanous PhD, The Lancet (2014) - doi:10.1016/S0140-6736(13)61939-X
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Parkinson's Disease category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Lancet, The. "First clinical study of new gene therapy shows promise for reducing motor symptoms of Parkinson's disease." Medical News Today. MediLexicon, Intl., 14 Jan. 2014. Web.
9 Mar. 2014. <http://www.medicalnewstoday.com/releases/271137>
Lancet, T. (2014, January 14). "First clinical study of new gene therapy shows promise for reducing motor symptoms of Parkinson's disease." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/271137.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.